ANTIVIRAL THERAPY IN PATIENTS WITH ANOGENITAL HERPESVIRUS INFECTION
- Authors: Rakhmatulina M.R.1
-
Affiliations:
- Federal Medical Biophysical Center, FBA of Russia
- Issue: No 6 (2017)
- Pages: 165-169
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/329734
- DOI: https://doi.org/10.18565/aig.2017.6.165-9
- ID: 329734
Cite item
Open Access
Access granted
Abstract
Objective. To systematize the results of investigating the clinical efficiency and safety of etiotropic antiviral therapy in patients with the different course of genital herpes. Material and methods. Foreign and Russian articles published on the investigation topic were analyzed. The search depth was 20 years. Results. The paper gives data on the efficiency of episodic and suppressive therapy in patients with anogenital herpes infection. Conclusion. The use of the antiviral drug valacyclovir in the therapy of genital herpes contributes to the reduction of the clinical severity and rates of recurrences, lowers the risk of potential transmission of herpes simplex virus, including asymptomatic virus shedding, and substantially improves quality of life in the patients.
Full Text
About the authors
Margarita Rafikovna Rakhmatulina
Federal Medical Biophysical Center, FBA of Russia
Email: ra.marg@yandex.ru
MD, Professor of the Department of Dermatovenereology and Cosmetology with the Course of Clinical Laboratory Diagnostics Moscow 123098, Zhivopisnaya str. 46, Russia
References
- Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission. http://www.who.int/ mediacentre/factsheets/fs400/ru/
- Рахматулина М.Р. Современные возможности терапии вирусных инфекций, передаваемых половым путем. Акушерство и гинекология. 2015; 7: 100-5.
- Белоусова Т.А., Горячкина М.В. Этиотропная терапия простого герпеса: фокус на валацикловир. РМЖ. 2015; 9: 520.
- Beauman J.G. Genital herpes: a review. Am. Fam. Physician. 2005; 72: 1527-34.
- Федеральные клинические рекомендации. Дерматовенерология 2015. М.: ДЭКС-ПРЭСС; 2016. 768с.
- Перламутров Ю.Н., Чернова Н.И. Эффективность валацикловира в терапии орофациального герпеса. РМЖ. 2013; 22: 1084-8.
- Халдин А.А., Гилядов А.Д., Быханова О.Н., Исаева Д.Р. Воспроизведенные ациклические синтетические нуклеозиды в этиотропной терапии рецидивов простого герпеса. Клиническая дерматология и венерология. 2014; 2: 79-83.
- Bodsworth N.J., Crooks R.J., Borelli S. et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin. Med. 1997; 73: 110-6.
- Strand A., Patel R., Wulf H.C. et al. Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir. Sex. Transm. Infect. 2002; 78: 435-9.
- Patel R., Bodsworth N.J., Woolley P. et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin. Med. 1997; 73: 105-9.
- Romanowski B., Marina R.B., Roberts J.N. Patients’ preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study. Sex. Transm. Dis. 2003; 30: 226-31.
- Brentjens M.H., Yeung-Yue K.A., Lee P.C. et al. Recurrent genital herpes treatments and their impact on quality of life. Pharmacoeconomics. 2003; 21: 853-63.
- Corey L., Wald A., Patel R. et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 2004: 350: 11-20
Supplementary files
